Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection

Pediatric Infectious Disease Journal

Volumn 22, Issue 11, 2003, Pages 1022-1024

  Maples, Holly D ^a   Stowe, Cindy D ^a   Saccente, Suzanne L ^a   Jacobs, Richard F ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Infant; Skin infection; Trichosporon beigelii; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FOSPHENYTOIN SODIUM; PHENOBARBITAL; VORICONAZOLE;

ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; HEMOPHAGOCYTIC SYNDROME; HISTIOCYTOSIS; HUMAN; INFANT; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; SEIZURE; SKIN BIOPSY; TREATMENT OUTCOME; TRICHOSPORON BEIGELII; TRICHOSPORON BEIGELII INFECTION;

ANTIFUNGAL AGENTS; FATAL OUTCOME; HUMANS; INFANT; MYCOSES; NEUTROPENIA; PYRIMIDINES; TRIAZOLES; TRICHOSPORON;

EID: 0345276593     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000095167.38306.76     Document Type: Article

References (10)

1. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46:1144-6.
2. Fournier S, Pavageau W, Feuillhade M, et al. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 2002;21:892-6.
3. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21: 240-8.
4. Walsh TJ, Wood N, Milligan P, et al. Pharmacokinetics of intravenous voliconazole in children after single and multiple dose administration [Abstract A-17]. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 22 to 25, 2001. Washington, DC: American Society for Microbiology, 2001:2.
5. Pennick GJ, Clark M, Sutton DA, Rinaldi MG. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47:2348-50.
6. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
7. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546-53.
8. Jabado N, Casanova JL, Haddad E, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 1998;27: 1437-41.
9. van't Hek LG, Verweij PE, Weemaes CM, van Dalen R, Yntema J, Meis JF. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 1998;157:1694-6.
10. Andersson T, Hassall E, Lundborg P, et al. Pharmacokinetics of orally administered omeprazole in children. Am J Gastroenterol 2000;95:3101-6.